Biotechnology
InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
NANJING, China, Nov. 21, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against cancer treatment resistance and metastasis, announced that China National Medical Products Administration (NMPA) has granted Ifebemtinib (IN10018) Breakthr...
2024-11-21 15:09
1625
DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation
This partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform, capitalizing on their respective strengths. The overall optimization of the ADC drug has been achieved in a relatively short time. BEIJING, Nov. 20, 2024 /PRNewswi...
2024-11-21 13:01
1215
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRIIA) Antagonistic Monoclonal Antibody (mAb) for muscle-preservingweight loss in Obesity LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK) ("Laekna"), a global biotech compan...
2024-11-20 22:00
1641
CABIO Deepens Commitment to Global Markets, Aiming to Serve International Clients and Pursue Long-Term International Partnerships
FRANKFURT, Germany, Nov. 20, 2024 /PRNewswire/ -- CABIO, a high-tech enterprise underpinned by biotechnology and listed on the Science and Technology Innovation Board (stock code: 688089), unveiled its innovative product, NeoHMOs®, at the Food Ingredients Europe event held inFrankfurt, Germany. ...
2024-11-20 21:00
1014
2024 Global Healthy Longevity Conference Successfully Held
SHENZHEN, China, Nov. 20, 2024 /PRNewswire/ -- The 2024 Global Healthy Longevity Conference took place successfully in Shenzhen from 15-17 November. Under the theme "The Healthy Longevity Era: Technology-driven Anti-Aging," the conference combined exhibitions and forum presentations to explore ke...
2024-11-20 19:13
1263
Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B
SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA) from the New Zealand Medicines and Medical Devices Safe...
2024-11-20 07:20
1262
Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS
NANTONG and SUZHOU, China, Nov. 19, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-21, its novel siR...
2024-11-19 21:26
1164
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Highlights: * Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) * Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~...
2024-11-19 20:30
1272
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
* SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using analpha-particle emitting radioisotope, actinium-225, for potential cancer treatments * The two sides aim to submit an Investigatio...
2024-11-19 08:00
1672
C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital
CHENGDU, China, Nov. 18, 2024 /PRNewswire/ -- In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C Ray"), an innovative enterprise in the field of radiopharmaceuticals, announced the completion of its Series A+ financing round exceeding$100 million. This round ...
2024-11-18 22:00
1754
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
* Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed$900M with tiered single digit sal...
2024-11-18 21:50
1335
FDA Grants Breakthrough Therapy Designation to Huahui Health's Libevitug (HH-003) for treatment of chronic Hepatitis D virus infection
BEIJING, Nov. 18, 2024 /PRNewswire/ -- Huahui Health, a clinical-stage biotechnology company focused on discovering and developing novel therapies in the areas of viral hepatitis, hepatology, and oncology, today announced that its investigational hepatitis D and B drug candidate, Libevitug (HH-00...
2024-11-18 18:40
1067
SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors
TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd.
2024-11-18 08:00
1238
Neurophet Appoints CTO Donghyeon Kim as Co-CEO, Joining Jake Junkil Been in Dual Leadership to Drive Global Growth
- Donghyeon Kim, Co-Founder and CTO of Neurophet, to Take On Dual Role as CEO, Heading Technology and Company Leadership - Aims to Strategically Expand Business and Management Functions for Establishing a Strong Presence in Global Markets SEOUL, South Korea, Nov. 15, 2024 /PRNewswire/ -- Neuroph...
2024-11-15 22:00
1660
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease
* IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program * ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) * The planned clinical ...
2024-11-15 20:00
1314
Angel Yeast Turns Automation into Opportunity, Ensuring No Job Losses
YICHANG, China, Nov. 15, 2024 /PRNewswire/ -- Angel Yeast has taken a significant step towards modernization and sustainability by automating its packaging line while ensuring no layoffs for its employees. In 2024, with the completion of the intelligent transformation of its packaging workshop, t...
2024-11-15 20:00
1351
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2024-11-15 09:55
1313
I-Mab Reports Third Quarter 2024 Results
* Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data * On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 * Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 * Estimated cash ru...
2024-11-14 20:00
1072
Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.
PISCATAWAY, N.J., Nov. 13, 2024 /PRNewswire/ -- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments from capital markets. To strengthen this vital sector, GenScript is bringing together leading sc...
2024-11-13 23:51
1051
Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AI
Highlights: * ISM001-055 was safe and well-tolerated with a favorable PK profile in IPF patients * Patients who received ISM001-055 showed dose-dependent improvement in the efficacy endpoint, as measured by change in forced vital capacity (FVC) at 12 weeks CAMBRIDGE, Mass., Nov. 12, 2024 /...
2024-11-12 22:00
1319
Week's Top Stories
Most Reposted
UTP LAUNCHES MALAYSIA'S FIRST BACHELOR IN INTEGRATED ENGINEERING PROGRAMME
[Picked up by 315 media titles]
2024-12-27 13:17
COCONEXT 2024 - FIRST EVER INTERNATIONAL COCONUT CONFERENCE HOLD IN VIETNAM
[Picked up by 298 media titles]
2024-12-31 14:18
Dahua Technology Obtains ISO 37301 Compliance Management System Certification
[Picked up by 280 media titles]
2024-12-30 15:33
Russell Reynolds Associates Appoints Euan Kenworthy as Singapore Country Manager
[Picked up by 273 media titles]
2025-01-02 08:16
CKGSB Professor Mei Jianping Launches Global Indices Tracking Impressionist, Contemporary, and Chinese Art Markets
[Picked up by 257 media titles]
2024-12-31 22:30Most Read
UTP LAUNCHES MALAYSIA'S FIRST BACHELOR IN INTEGRATED ENGINEERING PROGRAMME
2024-12-27 13:17
12740
Huawei Cloud Named a Challenger in Gartner® Magic Quadrant™ for Cloud DBMSs
2024-12-27 11:24
10835
/C O R R E C T I O N -- Ellington Properties/
2024-12-27 20:57
10085
Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference
2024-12-27 09:44
8182